A

STUDY ON
"TRAINING AND DEVELOPMENT"
With reference to
"HETERO LABS LIMITED (UNIT-III) "
NAKKAPALLI MANDAL, VISAKHAPATNAM.

A project report submitted to

The Department of Commerce and Management Studies,
Adikavi nannaya University, Rajamahendravaram, in partial
fulfilment of the requirements for the awards of the Degree
of
MASTER OF BUSINESS ADMINISTRATION

Submitted by
Bandharu Ratnakumar
REGD.NO: 203103

Under the Guidance of

MR.K.S.V.N.SATYANARAYANA, MBA.
PROFESSOR

DEPARTMENT OF MANAGEMENT STUDIES

D.N.R. SCHOOL OF BUSINESS MANAGEMENT
(APPROVED BY AICTE, NEW DELHI and Affiliated
to Adikavi Nannaya University, Rajamahendravaram)
BALUSUMUDI, BHIMAVARAM
WEST GODAVARI - 534202
(2020 – 2022)
1
1.College CERTIFICATE

2
2.Completing Certificate

3
 DECLARATION

This is to certify that project report titled " TRANING

AND DEVELOPMENT" with reference to HETERO
LABS LIMITED (UNIT-III), VISAKHAPATNAM.
Which is submitted by me in partial fulfilment of the
requirement for the degree of Master of Business
Administration to ADIKAVI NANNAYA UNIVERSITY,
RAJAMAHENDRAVARAM comprises my original
work and due acknowledgement has been made in
text to all other text material used.

I further declare that to the best of my knowledge

and belief that the project report does not contain any
part of any work which has been submitted for the
award of any other degree/diploma/certificate in this
University or any other universities.

Place: Bhimavaram
Date:

(BANDHARU RATNAKUMAR)
Regd.No: 203103
4
 ACKNOWLEDGEMENT
I sincerely acknowledge my grateful thanks to Sri. G. V. NARASIMHA
RAJU Garu, President and Sri G. SATYANARAYANA RAJU Garu,
Secretary & Correspondent, D.N.R. College Educational Institutions for
providing me opportunity and lending his support to do the project work.

My grateful thanks to Dr. D. VENKATAPATHI RAJU, Principal, D.N.R.

School of Business Management for giving me an opportunity to do this
project work.

My sincere thanks goes to MUNTA DURGA SRINIVAS SR.

MANAGER- HR OF HETERO LABS LIMITED (UNIT-III),
VISAKHAPATNAM for giving permission to carry out this work and
monitored my progress and arranged all facilities to make life easier.

I am greatly indebted to, Dr.K. NARENDRA KUMAR Professor who

inspire of being extraordinarily busy with his duties, took time out to hear, to
guide and keep me on correct path.

Finally, I thank my beloved PARENTS who helped me, encourage me and

strengthened me for successful completion of the project. I also thank all
my friends, relatives and all my well-wishers who have directly or
indirectly contribute their help in the successful
completion of my project work.

I bow down to my all mighty.

BHIMAVARAM.
Date:
(BANDHARU RATNAKUMAR)

5
 INDEX

CHAPTER TITLE PAGE NO.

CHAPTER-I INTRODUCTION 1- 6
IMPORTANCE OF THE STUDY
NEED FOR THE STUDY
OBJECTIVES OF THE STUDY
SCOPE OF THE STUDY
METHODOLOGY OF THE STUDY
LIMITATIONS OF THE STUDY

CHAPTER-II INDUSTRY PROFILE 7-13

CHAPTER-III COMPANY PROFILE 14-21

CHAPTER-IV QUESTIONNAIRE 22-40

CHAPTER-V DATA ANALYSIS AND 41-63

INTERPRETATION

CHAPTER-VI FINDINGS, SUGGESTIONS AND 64-66

CONCLUSION

BIBLIOGRAPHY 67
ANNEXURE 68-72

6
 CHAPTER-1

➢ INTRODUCTION
➢ IMPORTANCE OF THE STUDY
➢ NEED FOR THE STUDY
➢ OBJECTIVES OF THE STUDY
➢ SCOPE OF THE STUDY
➢ METHODOLOGY OF THE STUDY
➢ LIMITATIONS OF THE STUDY

7
INTRODUCTION

8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
 HETERO LABS

Hetero is a globally renowned vertically integrated

pharmaceutical player engaged in research and development,
manufacturing, and marketing of high-quality chemical and
biologic medicines across diverse therapeutic areas. Backed by
27+ years of expertise in the pharmaceutical industry, Herero’s
strategic business areas spread across APIs, Global Generics,
Biosimilars and Custom Pharmaceutical Services. The
company is among the largest producers of Active
Pharmaceutical Ingredients (APIs) in the world.

Hetero has 36 state-of-the-art manufacturing facilities

strategically located worldwide, which has been approved by
top pharma regulatory bodies of the world. Our portfolio
includes 300+ products encompassing major therapeutic
categories such as HIV/AIDS, Oncology, Cardiovascular,
Neurology, Hepatitis, Nephrology etc. Hetero has a strong
global presence in over 126 countries and focusses on making
affordable medicines accessible to patients worldwide.

Over the years, Hetero has established its strong leadership in

ARVs and Antiviral therapies and caters to 40% of existing
global demand for Anti-Retroviral (ARV) APIs and Finished
Dosage Forms (FDFs) used in HIV/AIDS treatment.

23
A track record of responding to Global Public
Health Emergencies

The highlight of Herero’s 27+ years of existence has been its

responsive actions to mitigate pandemics and life-threatening
diseases afflicting communities across the world. By
partnering with innovators for developing Oseltamivir to fight
against Swine Flu Pandemic to enabling access to affordable
Hepatitis C medicines in underdeveloped countries, Hetero has
always endeavoured to do its bit at times of global health crises
and save precious lives.

Since the onset of the Covid-19 pandemic, Hetero has been

proactive in responding to the various challenges surrounding
it. It has been the first company to launch the licensed version
of generic Remdesivir under the brand name ‘Covifor’ in India for
treating severely infected patients and followed it up with
Favipiravir (Favivir) to provide succour to those affected by mild
and moderate symptoms. As of today, the company is among
the largest manufacturers of Remdesivir globally.

Illustrating its continuing commitment to play its part in the

global fight against the pandemic, Hetero has entered into an
agreement with the Russian Direct Investment Fund (RDIF) as a
manufacturing partner for producing 100 million doses of the
Sputnik V vaccine per year. This development also showcases

24
Hetero’s enduring spirit of collaboration and penchant for
contributing to global health and well-being.

Type Private
Industry Pharmaceuticals
Founded 1993
Founder Dr BPS Reddy
Headquarters Hyderabad India
Key people Dr. Vamsi Reddy
Number of employees Over 22,000

Operations

"Hetero group employs over 21,000 people. Hetero is a player in

the active pharmaceutical ingredients market and finished
dosages. It has marketing presence in over 127 countries.

25
Hetero has supplied antiretroviral drugs to patients across more
than 100 countries globally.

Today, Oseltamivir, sold under its brand name Fluvir, is also

indicated for A[H1N1] virus, also known as swine flu. [citation
needed]

Hetero also produces hepatitis C antivirals such as Sofovir

(sofosbuvir) and Ledifos (a fixed-dose combination of sofosbuvir
and ledipasvir). [citation needed]

Company structure

Hetero Group's subsidiaries include Hetero Drugs, Hetero Labs,

Hetero Research Foundation, Genx Laboratories and also foreign
subsidiaries such as Camber Pharma Inc. in United States, Hetero
Europe in Europe, and Richmond Labs in Argentina. The group is
also investing in the wind power industry with a goal to reach
26
1000 megawatts by 2017.

2009 Swine flu outbreak

In 2009, as the swine flu outbreak was spreading across the globe
and various health organizations and government agencies were
piling up stocks of Oseltamivir as precautionary measures, Hetero
supplied generic Oseltamivir under its brand name Fluvir.

Hetero delivered 10 million doses of Oseltamivir to the Indian

government in 2009, and shipped about 80 million doses to over
60 countries. Hetero received its second order from Indian
government to supply another 10 million doses of Oseltamivir
later in 2009.

COVID-19 experimental drugs

The company has launched the generic version of experimental

COVID-19 drug Remdesivir under brand name Covifor after
acquiring license from Gilead Sciences and obtaining approval
from CDSCO, the Indian drug control authority. On July 29, 2020
the company launched its version of the anti viral drug Favipiravir
under the brand name Favivir, after getting approval from Drugs
27
Controller General of India (DCGI), used in the treatment of mild
to moderate COVID-19 patients. On November 27, 2020, Hetero
Labs signed an agreement with the Russian Direct Investment
Fund (RDIF) to manufacture 100 million doses of the Sputnik V
vaccine.

References

"Archived copy". Archived from the original on 16 September

2016. Retrieved 11 July 2016.CS1 maint: archived copy as title
(link)

":: Welcome to Hetero ::". Heterodrugs.com. Archived from the

original on 17 January 2014. Retrieved 11 January 2014.

28
"Hetero Wind power". Hetero. Retrieved 22 June 2018.

Swine flu: Centre taps Hetero for generic Tamiflu supply Archived
30 April 2009 at the Way back Machine

Khomba Singh, ET Bureau 5 May 2009, 12.03am IST (5 May 2009).

"Hetero bags mega chunk of govt's anti-flu drug deal - Economic
Times". Economictimes.indiatimes.com. Retrieved 11 January
2014.CS1 maint: multiple names: authors list (link)

"Hyderabad pharma cos cash in on Swine-Flu fever".

Moneycontrol.com. Retrieved 11 January 2014.

Khomba Singh, ET Bureau 22 August 2009, 03.02am IST (22 August

2009). "Hetero bags deal for 10 m Tamiflu - Economic Times".
Economictimes.indiatimes.com. Retrieved 11 January 2014.CS1
maint: multiple names: authors list (link)

"Covid-19: Hyderabad-based Hetero Labs Ltd prices generic

version of remdesivir at Rs 5,400 per vial". The Indian Express. 25
June 2020.

Kumar, N. Ravi (29 July 2020). "India's Hetero Labs wins approval
to sell COVID-19 drug favipiravir". The Hindu. ISSN 0971-751X.
Retrieved 9 September 2020.

Das, Sohini (27 November 2020). "Hetero Labs to manufacture

100 Mn doses of Sputnik V vaccine for India". Business Standard
India. Retrieved 28 November 2020."

29
30